mProX™ Human NMUR2 Stable Cell Line

Botticelli L, et al. "The neuromedin U system: Pharmacological implications for the treatment of ." Pharmacological research, 2023.
Neuromedin U (NMU) is a significant bioactive peptide that is produced both in the gut and in the brain. It plays a crucial role in various physiological processes. By activating the NMU receptor 1 (NMU-R1), which is primarily found in the peripheral nervous system, and the NMU receptor 2 (NMU-R2), which is mainly expressed in the central nervous system, NMU exerts its effects. Observations have shown that NMU is an essential neuropeptide involved in the regulation of food intake, demonstrating powerful anorexigenic capabilities. Studies using genetically modified animals have revealed that the absence of the NMU gene leads to an obesity phenotype, indicating the potential of NMU analogs or NMU-R2 agonists in treating obesity. Additionally, NMU has also been linked to non-homeostatic food intake, suggesting a possible role in binge eating behavior. This review summarizes the current knowledge on the relationship between the NMU system and obesity and binge eating behavior, with a focus on NMU's influence on food intake and the neuronal mechanisms underlying its anti-obesity effects. Additionally, potential pharmacological strategies to improve the pharmacokinetic profile of NMU will also be discussed.
Pubmed: 37517560   DOI: 10.1016/j.phrs.2023.106875

Palasz A, et al. "Pharmacomodulation of brain neuromedin U signaling as a potential therapeutic ." Journal of neuroscience research, 2023.
Neuromedin U (NMU) is a neuropeptide that plays a role in regulating various neurophysiological functions through its interaction with the metabotropic receptor NMUR2. Its involvement in processes such as energy balance, stress response, circadian rhythms, and endocrine signaling makes it a potential target for pharmacological modulation. Preclinical studies show that modified NMU analogues such as PASR8-NMU and F4R8-NMU, as well as NMUR2 agonists like CPN-116 and CPN-124, exhibit notable pharmacological activity when administered through the nasal route. These compounds have the potential to provide more convenient and safer treatment options for conditions such as obesity, eating disorders, Alzheimer's disease, alcohol addiction, and sleep disturbances. The growing evidence suggests that targeting the central NMU signaling may be a promising approach in managing various neuropsychiatric disorders.
Pubmed: 37496289   DOI: 10.1002/jnr.25234